Cargando…
Huangkui Capsule in Combination with Leflunomide Improves Immunoglobulin A Nephropathy by Inhibiting the TGF-β1/Smad3 Signaling Pathway
OBJECTIVES: To investigate the efficacy and potential molecular mechanism of Huangkui capsule in combination with leflunomide (HKL) for the treatment of immunoglobulin A nephropathy (IgAN) METHODS: IgAN rat models were constructed by treating rats with bovine serum albumin, lipopolysaccharide, and t...
Autores principales: | Pei, Shuwen, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculdade de Medicina / USP
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614623/ https://www.ncbi.nlm.nih.gov/pubmed/34909911 http://dx.doi.org/10.6061/clinics/2021/e2904 |
Ejemplares similares
-
Clinical Efficacy of Huangkui Capsule Plus Methylprednisolone for Immunoglobulin A Nephropathy and Its Effect on Renal Function and Serum Inflammatory Factors
por: Yuan, Lili, et al.
Publicado: (2023) -
Efficacy and safety of Huangkui capsule for diabetic nephropathy: A protocol for systematic review and meta-analysis
por: An, Wenrong, et al.
Publicado: (2021) -
Clinical Efficacy of Huangkui Capsule plus Methylprednisolone in the Treatment of Nephropathy and the Effect on Urinary Protein and Serum Inflammatory Factors in Patients
por: Wan, Weibo, et al.
Publicado: (2022) -
Network pharmacology and molecular docking predictions of the active compounds and mechanism of action of Huangkui capsule for the treatment of idiopathic membranous nephropathy
por: Cai, Meng, et al.
Publicado: (2023) -
Inhibition of Akt/mTOR/p70S6K Signaling Activity With Huangkui Capsule Alleviates the Early Glomerular Pathological Changes in Diabetic Nephropathy
por: Wu, Wei, et al.
Publicado: (2018)